]>
IRCT2017051533976N1 IRCT 2017-06-03 Vice chancellor for research of Shiraz University of Medical Sciences Iron supplementation in pregnancy Evaluation of the effect of Iron supplement use on pregnancy outcomes in women without iron deficiency referred to Hazrat zeynab and Hafez gynecology clinic in 2016 2017-03-20 anticipated 90 Complete https://irct.ir/trial/26103 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention. N/A Iron deficiency anemia in pregnancy. Intervention 1: Group A: Pregnant women who fit their iron stores (serum ferritin level <30 ppm) and typically take 60 mg/day ferrous sulfate. Intervention 2: The second group of pregnant women with thalassemia minor levels of serum ferritin them more than 30 micrograms per liter is needed to get pills of iron supplements are pregnant women that the serum ferritin is greater than 30 micrograms per deciliter is and because of intolerance to oral ferrous sulfate (gastrointestinal symptoms such as nausea, bloating and constipation), do not use supplements. Intervention 3: The third group of pregnant women that their ferritin level of less than 30 micrograms per deciliter of iron deficiency and 60 mg/day iron supplements they consume.
public Dr. Leilyia Abassi
Shiraz University of Medical Sciences، Zand street
Shiraz Iran (Islamic Republic of) +98 71 3233 2365 hafez_perina@sums.ac.ir Shiraz University of Medical Sciences scientific Dr. Azam Faraji
Shiraz University of Medical Science, Zand Street
Shiraz Iran (Islamic Republic of) +98 71 3233 2365 farajiaz@sums.ac.ir Shiraz University of Medical Science Iran (Islamic Republic of) Inclusion criteria: Age between 18 to 40 years without any underlying condition such as diabetes, hypertension, liver disease and kidney disease, heart disease and vascular, no history of pregnancy complications included preeclampsia, gestational diabetes, premature labor, miscarriage, stillbirth and low birth weight in previous pregnancies, no risk factors for pre-eclampsia, gestational diabetes and IUGR. Exclusion criteria: younger than 18 and older than 40 years, having a risk factor for preeclampsia, gestational diabetes and IUGR, diabetes, obesity, multiple pregnancy, cardiovascular disease, kidney disease, connective tissue disease and history of preeclampsia in a previous pregnancy, having a history of pregnancy complications in previous pregnancies. 18 years 40 years Female D50.8 Other iron deficiency anaemias Treatment - Drugs Treatment - Drugs Treatment - Drugs Group A: Pregnant women who fit their iron stores (serum ferritin level <30 ppm) and typically take 60 mg/day ferrous sulfate. The second group of pregnant women with thalassemia minor levels of serum ferritin them more than 30 micrograms per liter is needed to get pills of iron supplements are pregnant women that the serum ferritin is greater than 30 micrograms per deciliter is and because of intolerance to oral ferrous sulfate (gastrointestinal symptoms such as nausea, bloating and constipation), do not use supplements The third group of pregnant women that their ferritin level of less than 30 micrograms per deciliter of iron deficiency and 60 mg/day iron supplements they consume. Hemoglobin level. Timepoint: At first, seconed and third trimister pregnancy. Method of measurement: Laboratory. Serum ferritin level. Timepoint: At first, seconed and third trimister pregnancy. Method of measurement: Laboratory. MCV level. Timepoint: At first, seconed and third trimister pregnancy. Method of measurement: Laboratory. MCH level. Timepoint: At first, seconed and third trimister pregnancy. Method of measurement: Laboratory. Serum iron level. Timepoint: At first, seconed and third trimister pregnancy. Method of measurement: Laboratory. Vice chancellor for research of Shiraz University of Medical Sciences Approved 2017-04-19 Ethics committee of Shiraz University of Medical Sciences Shiraz University of Medical Sciences، Zand Street، Shiraz Shiraz Iran (Islamic Republic of)